Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.00 EUR
Change Today -0.038 / -3.68%
Volume 0.0
RYIN On Other Exchanges
As of 3:09 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Eric H. Bjerkholt

Chief Financial Officer, Executive Vice President of Corporate Development & Finance and Corporate Secretary,Sunesis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 24 board members in 3 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Eric H. Bjerkholt has been the Chief Financial Officer of Sunesis Pharmaceuticals, Inc., since January 2004 and has also been its Executive Vice President of Corporate Development & Finance since February 2, 2012. Mr. Bjerkholt also serves as Secretary of Sunesis Pharmaceuticals, Inc. and previously served as its Senior Vice President of Corporate Development and Finance and Chief Financial Officer from February 2007 to January 2012. He has several years of experience ...

Read Full Background

Corporate Headquarters*

395 Oyster Point Boulevard
South San Francisco, California 94080

United States

Phone: 650-266-3500
Fax: 650-266-3501

Board Members Memberships*

Director, Chairman of Audit Committee, Member of Compensation & Stock Option Committee and Member of Strategic Transactions Committee
Director and Chairman of Audit Committee


Harvard Business School
Bachelor's Degree
Oslo and Akershus University College of Applied Sciences

Other Affiliations*

Annual Compensation*

Total Annual Compensation$390,062

Stock Options*

All Other Compensation$4,306
Exercisable Options681,158
Unexercisable Options380,002
Total Number of Options1,061,160

Total Compensation*

Total Annual Cash Compensation$511,868
Total Short Term Compensation$390,062
Other Long Term Compensation$4,306
Total Calculated Compensation$1,253,630
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RYIN:GR €1.00 EUR -0.038


Adrian Adams Chief Executive Officer and Director
Compensation as of Fiscal Year --.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at